Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo Production of Antibody Therapeutics in Patients

Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo Production of Antibody Therapeutics in Patients September 2, 2020 at 9:00 AM EDT Download PDF SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: [...]

By |2020-09-10T12:50:17-04:00September 10th, 2020|Press Releases|0 Comments

Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies to Treat COVID-19 and Cancer Therapeutics

Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies to Treat COVID-19 and Cancer Therapeutics The combination of SmartPharm’s Gene Mab™ gene-encoded in vivo expression system and Sorrento’s SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. Beyond COVID-19, [...]

By |2020-08-20T17:30:55-04:00August 20th, 2020|Press Releases|0 Comments

Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics

Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics The combination of SmartPharm's Gene Mab™ gene-encoded in vivo expression system and Sorrento's SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. The [...]

By |2020-07-24T18:47:45-04:00July 24th, 2020|Press Releases|0 Comments

Sorrento Therapeutics and SmartPharm Therapeutics Announce Intention to Collaborate to Develop Novel Gene-Encoded Antibody Vaccine Intended for COVID-19

For Immediate Release March 23, 2020     SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19 Collaboration to leverage synergies between Monoclonal Antibody and Non-Viral Gene Delivery Platforms SAN DIEGO and BOSTON, March 23, 2020 /GlobeNewswire/ -- In response to the government call for rapidly deployable countermeasures, [...]

By |2020-03-23T10:00:18-04:00March 23rd, 2020|Press Releases|0 Comments

SmartPharm Therapeutics Appoints John T. Potts, MD, DSc, to Board of Directors

CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced the appointment of John T. Potts, MD, DSc, to its Board of Directors. Dr. Potts' distinguished, five-decade career in healthcare and the life sciences spans medical [...]

By |2019-10-21T13:37:57-04:00October 21st, 2019|Press Releases|0 Comments

SmartPharm Therapeutics Announces Presentation at the 2019 BIO Investor Forum

SmartPharm Therapeutics Announces Presentation at the 2019 BIO Investor Forum CAMBRIDGE, Mass., Oct. 16, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, Chief Executive Officer, will present at the 2019 BIO [...]

By |2019-11-01T14:23:12-04:00October 16th, 2019|Press Releases|0 Comments

SmartPharm Therapeutics Announces Presentation at the Chardan 3rd Annual Genetic Medicines Conference

SmartPharm Therapeutics Announces Presentation at the Chardan 3rd Annual Genetic Medicines Conference CAMBRIDGE, Mass. – September 30, 2019 – SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, President and Chief Executive Officer, will present [...]

By |2019-09-30T10:32:50-04:00September 30th, 2019|Press Releases|0 Comments

SmartPharm Therapeutics Appoints Fred Driscoll to Board of Directors

SmartPharm Therapeutics Appoints Fred Driscoll to Board of Directors Published: Sep 05, 2019 CAMBRIDGE, Mass., Sept. 5, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced the appointment of Fred Driscoll to its Board of Directors. Mr. [...]

By |2019-09-05T11:15:42-04:00September 5th, 2019|Press Releases|0 Comments

SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer

SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer CAMBRIDGE, Mass. – June 25, 2019 – SmartPharm Therapeutics, a pre-clinical stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, has been appointed Chief Executive Officer. Dr. [...]

By |2019-06-28T12:49:33-04:00June 25th, 2018|Press Releases|Comments Off on SmartPharm Therapeutics Appoints José Trevejo, MD, PhD, as Chief Executive Officer
Go to Top